Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

Helicobacter Pylori

Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial

Lancet Infect Dis.

Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.

doi: 10.1016/S1473-3099(19)30272-5.

Beneficial effect of Burdock complex on asymptomatic Helicobacter pylori-infected subjects: A randomized, double-blind placebo-controlled clinical trial

Helicobacter.

Yen CH, Chiu HF, Huang SY, Lu YY, Han YC, Shen YC, Venkatakrishnan K, Wang CK

doi: 10.1111/hel.12469.

Helicobacter Pylori

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Gut.

Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K

doi: 10.1136/gutjnl-2019-319954.

Helicobacter Pylori

Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota

J Gastroenterol Hepatol.

Liou JM, Lee YC, Wu MS

doi: 10.1111/jgh.14992.

Helicobacter Pylori

Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis

Helicobacter.

Ye Q, Shao X, Shen R, Chen D, Shen J

doi: 10.1111/hel.12713.

Helicobacter Pylori

Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies

Helicobacter.

Dore MP, Bibbò S, Loria M, Salis R, Manca A, Pes GM, Graham DY

doi: 10.1111/hel.12659.

Helicobacter Pylori

PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis

Helicobacter.

Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, Lu H

doi: 10.1111/hel.12692.

Helicobacter Pylori

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection

Helicobacter

Kim YJ, Chung WC, Kim DB

doi: 10.1111/hel.12792

Helicobacter Pylori

Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children

Helicobacter.

Zhou Y, Ye Z, Wang Y, Zhang Y, Tang Z, Yan W, Jiang Y, Huang Y

doi: 10.1111/hel.12679.

Related content

Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial

Beneficial effect of Burdock complex on asymptomatic Helicobacter pylori-infected subjects: A randomized, double-blind placebo-controlled clinical trial

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota

Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis

Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies

PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection

Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children